New data from IONIS-HTT Rx phase 1/2 study demonstrates positive results
Ionis Pharma announced top-line data from the Phase 1/2 study of IONIS-HTTRx in people with early stage Huntington's disease. Results from exploratory analyses of data from the study demonstrated correlations between reductions in mutant mHTT and improvements in clinical measures. April 24, 2018